EcoDrugPlus

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSCHYG00000002094
Gene Symbol: CXCL8
1 Cross references
139 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSCHYG00000012367
Gene Symbol: CXCR4
1 Cross references
218 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCHYG00000006329
Gene Symbol: CFTR
1 Cross references
217 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSCHYG00000001426
Gene Symbol: DNMT1
1 Cross references
212 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSCHYG00000004090
Gene Symbol: TOP2A
1 Cross references
206 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSCHYG00000009238
Gene Symbol: TOP2B
1 Cross references
210 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSCHYG00000011900
Gene Symbol: EML4
1 Cross references
214 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSCHYG00000002205
Gene Symbol: EPHA2
1 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSCHYG00000025451
Gene Symbol: EPHA3
1 Cross references
216 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSCHYG00000016103
Gene Symbol: EPHB4
1 Cross references
168 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSCHYG00000001584
Gene Symbol: F2RL3
1 Cross references
193 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSCHYG00000024400
Gene Symbol: FYN
1 Cross references
264 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).